Setmelanotide vs PT-141

Both act at MC4R, yet were developed for different outcomes: setmelanotide for hunger in genetic obesity, PT-141 for sexual desire. The contrast shows how widely MC4R signalling reaches.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Setmelanotide

A melanocortin-4 receptor agonist approved for rare genetic obesities caused by defects in the leptin–melanocortin pathway.

BEST STUDIED FOR

Melanocortin

Read the cited profile →

🧪

PT-141

A cyclic melanocortin-receptor agonist derived from melanotan II, approved in the US for hypoactive sexual desire disorder in premenopausal women.

BEST STUDIED FOR

Melanocortin

Read the cited profile →

SIDE BY SIDE

	Setmelanotide	PT-141
The key difference	MC4R agonist — appetite	MC3R/MC4R agonist — sexual function
Class	Melanocortin	Melanocortin
Mechanism	MC4R neurons integrate leptin and POMC signals to regulate hunger and energy expenditure.	Bremelanotide activates melanocortin receptors (mainly MC4R, also MC1R) in the central nervous system.
Status	Approved (2020 onward) for POMC, PCSK1 or LEPR deficiency obesity and Bardet–Biedl syndrome; studied in hypothalamic obesity.	FDA-approved (2019) for acquired, generalised HSDD in premenopausal women; earlier developed as a nasal spray for erectile dysfunction.
Reported safety signals	Trials report injection-site reactions and skin hyperpigmentation (an expected MC1R effect), with nausea early in treatment.	Approval-era data list nausea, flushing and transient blood-pressure increase; focal hyperpigmentation has been reported with repeated use.
A key study	Summarises setmelanotide’s development and first approval for POMC, PCSK1 or LEPR deficiency obesity. (Drugs 2021, PMID 33638809)	Summarises the development and 2019 US approval of bremelanotide as a melanocortin receptor agonist for HSDD. (Drugs 2019, PMID 31429064)

WHEN TO RESEARCH WHICH

The pair is useful for research on how one receptor drives distinct behaviours. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Setmelanotide] Setmelanotide: First Approval — Drugs 2021. PMID 33638809
[Setmelanotide] Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials — Lancet Diabetes Endocrinol 2020. PMID 33137293
[Setmelanotide] Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period — Lancet Diabetes Endocrinol 2022. PMID 36356613
[PT-141] Bremelanotide: First Approval — Drugs 2019. PMID 31429064
[PT-141] PT-141 Palatin — Curr Opin Investig Drugs 2004. PMID 15134289
[PT-141] Targeting the central melanocortin system for the treatment of metabolic disorders — Nat Rev Endocrinol 2023. PMID 37365323

FREQUENTLY ASKED

What is the difference between Setmelanotide and PT-141?

Both act at MC4R, yet were developed for different outcomes: setmelanotide for hunger in genetic obesity, PT-141 for sexual desire. The contrast shows how widely MC4R signalling reaches.

What is the regulatory status of Setmelanotide and PT-141?

Setmelanotide: Approved (2020 onward) for POMC, PCSK1 or LEPR deficiency obesity and Bardet–Biedl syndrome; studied in hypothalamic obesity. PT-141: FDA-approved (2019) for acquired, generalised HSDD in premenopausal women; earlier developed as a nasal spray for erectile dysfunction.

What safety signals have been reported?

Setmelanotide: Trials report injection-site reactions and skin hyperpigmentation (an expected MC1R effect), with nausea early in treatment. PT-141: Approval-era data list nausea, flushing and transient blood-pressure increase; focal hyperpigmentation has been reported with repeated use.

Which studies is this comparison based on?

For Setmelanotide: “Setmelanotide: First Approval” (PMID 33638809); “Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials” (PMID 33137293); “Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period” (PMID 36356613). For PT-141: “Bremelanotide: First Approval” (PMID 31429064); “PT-141 Palatin” (PMID 15134289); “Targeting the central melanocortin system for the treatment of metabolic disorders” (PMID 37365323).